Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
BridgeBio Pharma, Inc. - Common Stock
(NQ:
BBIO
)
68.69
-3.69 (-5.09%)
Streaming Delayed Price
Updated: 3:51 PM EDT, Sep 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about BridgeBio Pharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
BridgeBio (BBIO) Q2 2026 Earnings Call Transcript
↗
August 19, 2026
Attruby revenue surged to $222.4 million as three pipeline programs entered regulatory review.
Via
The Motley Fool
Topics
Earnings
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing
↗
August 16, 2026
Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think.
Via
The Motley Fool
BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.
↗
August 14, 2026
The company clearly has a winner on its hands with the recently approved Attruby.
Via
The Motley Fool
BridgeBio Pharma (NASDAQ:BBIO) Flashes Perfect Technical Score and Tight Breakout Setup
↗
August 11, 2026
Via
Chartmill
BridgeBio Pharma (NASDAQ:BBIO) Q1 2026 Revenue Beat Driven by Attruby Sales Surge, Shares Jump
↗
May 07, 2026
Via
Chartmill
BridgeBio Pharma Inc (NASDAQ:BBIO) Posts Q4 Revenue Beat on Heart Drug Surge, Eyes Multiple 2026 NDA Submissions
↗
February 24, 2026
Via
Chartmill
BridgeBio Pharma Q2 Earnings Call Highlights
↗
August 10, 2026
BridgeBio Pharma (NASDAQ:BBIO) reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026, while advancing three late-stage programs into regulatory review...
Via
MarketBeat
Topics
Earnings
1 Top Wall Street Analyst Thinks This Stock Could Soar 95% Over the Next 12 Months. Here's Why I Agree.
↗
August 02, 2026
Rapid commercial momentum could justify Wall Street's bullish outlook.
Via
The Motley Fool
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
↗
July 13, 2026
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.
Via
MarketBeat
There are notable gap-ups and gap-downs in today's session.
↗
July 09, 2026
Via
Chartmill
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.
↗
July 02, 2026
Analysts have given Alnylam Pharmaceuticals an average price target of $436.
Via
The Motley Fool
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches
↗
May 13, 2026
BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three...
Via
MarketBeat
BridgeBio (BBIO) Q1 2026 Earnings Transcript
↗
May 08, 2026
BridgeBio (BBIO) Q1 2026 Earnings Transcript
Via
The Motley Fool
BridgeBio (BBIO) Q2 2025 Earnings Transcript
↗
April 28, 2026
BridgeBio (BBIO) Q2 2025 Earnings Transcript
Via
The Motley Fool
Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
April 13, 2026
In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL...
Via
MarketMinute
Topics
Economy
BridgeBio Pharma Inc (NASDAQ:BBIO) Shows High Technical and Setup Ratings Ahead of Potential Breakout
↗
April 11, 2026
BridgeBio Pharma (BBIO) shows a strong technical uptrend with a high-quality consolidation pattern, signaling a potential breakout opportunity for traders.
Via
Chartmill
BridgeBio (BBIO) Q4 2025 Earnings Call Transcript
↗
February 24, 2026
BridgeBio (BBIO) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites
↗
February 17, 2026
Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.
Via
Stocktwits
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition
↗
February 17, 2026
Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.
Via
The Motley Fool
Topics
Regulatory Compliance
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough
↗
February 17, 2026
Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge
↗
February 17, 2026
This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates.
Via
The Motley Fool
Topics
Regulatory Compliance
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
February 12, 2026
As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as...
Via
Finterra
Topics
Economy
Intellectual Property
BBIO Stock Surges 17% Pre-Market Today – What’s Fueling The Rally?
↗
February 12, 2026
The company reported positive results from its PROPEL 3 study of its experimental oral therapy, infigratinib, in children with achondroplasia, a genetic form of dwarfism.
Via
Stocktwits
The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate
February 02, 2026
The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative...
Via
MarketMinute
Topics
ETFs
Government
Initial Public Offering
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance
January 02, 2026
In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to...
Via
MarketMinute
Topics
Economy
Intellectual Property
The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500
January 02, 2026
As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the...
Via
PredictStreet
Topics
Economy
Intellectual Property
Stocks
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?
↗
December 22, 2025
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?
Via
The Motley Fool
Topics
Regulatory Compliance
How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint
↗
December 02, 2025
Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam.
Via
Investor's Business Daily
BridgeBio (BBIO) Q3 2025 Earnings Call Transcript
↗
November 27, 2025
BridgeBio (BBIO) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
10 Health Care Stocks With Whale Alerts In Today's Session
↗
November 14, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
